Viridian Therapeutics IncVRDN
Price$20.59

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $71.1M+23,452.0% YoYTTM through 30 Jun 2026
Net Income -$387MTTM through 30 Jun 2026
Free Cash Flow -$335MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-569.0%
Operating Margin-82,389.4%
Net Margin-544.1%

Returns

-16.5%ROE
-13.3%ROA

Balance Sheet Health

Debt / Equity0.08x
Current Ratio15.15x
Net Debt-$711.7Mnet cash position
Cash & Equivalents$165M

Quality Metrics

Altman Z-Score1.41
Piotroski F-Score4 / 9
FCF Margin-471.0%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $70.8M
Diluted EPS
'20'21'22'23
FY2023: $-5.31

Dividend

No dividend

Capital Allocation

Capex Intensity2.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.